Log in for full access.

USF Home | USF Directory | myUSF

Monday-Thursday: 8AM – 6PM
Friday: 8AM – 5PM
Saturday-Sunday: Closed
Phone : (813) 974-4471
(Google Map)

Health Affairs, vol. 31 no. 10

Monday, October 15th, 2012 | Posted in Collections, Faculty, News, Students by Tomaro Taylor | Comments Off

The most recent edition of Health Affairs is available at the FMHI Research Library.

Volume 31, number 10: “Current Challenges in Comparative Effectiveness Research”

Comparative Effectiveness Research
A Symposium on Communication
Evidence, Care & Policy
Medicare Part D
Pharmaceuticals & Patents
Hospitals Medical Devices
Web First
Narrative Matters Grantwatch

Comparative Effectiveness Research

  • Five reasons that many comparative effectiveness studies fail to change patient care and clinical practice (Timble, Schneider, Van Busum, & Fox, p. 2168)
  • The patient-centered outcomes research institute should focus on high-impact problems that can be solved quickly (Sox, p. 2176)

A symposium on communication

  • Communicating about comparative effectiveness research: A health affairs symposium on the issues (Dentzer and the Editorial Team of Health Affairs, p. 2138)
  • Regulatory requirements of the Food and Drug Administration would preclude product claims based on observational research (Griffin, Godfrey, & Sherman, p. 2188)
  • Reviewing hypothetical migraine studies using funding criteria from the patient-centered outcomes research institute (Selby, Fleurence, Lauer, & Schneeweiss, 2193)
  • The Food and Drug Administration has the legal basis to restrict promotion of flawed comparative effectiveness research (Kesselheim & Avorn, 2200)
  • Academic detailing can play a key role in assessing and implementing comparative effectiveness research findings (Fischer & Avorn, p. 2206)
  • Communication about results of comparative effectiveness studies: A pharmaceutical industry view (Perfetto, Bailey, Jr., Gans-Brangs, Romano, Rosenthal, and Willke, p. 2213)
  • Congress should clarify the circumstances under which drug makers can communicate results on comparative effectiveness (Klasmeier, p. 2220)
  • The hypothetical migraine drug comparative effectiveness study: A payer’s recommendations for obtaining more useful results (Epstein, p. 2225)
  • Among other flaws, hypothetical migraine study lacks independent evaluation and patient engagement (Boutin, p. 2231)
  • Enhancing patient autonomy through peer review to replace the FDA’s rigorous approval process (Caplan, p. 2236)
  • How can policy protect public health and still foster innovation (p. 2241)

Evidence, Care and Policy

  • Evidence of no benefit from knee surgery for osteoarthritis led to coverage changes and is linked to decline in procedures (Howard, Brophy, & Howell, p. 2242)
  • The contribution of prevention and treatment to the decline in cardiovascular mortality: Lessons from a forty-year debate (Jones & Greene, p. 2250)

Medicare Part D

  • The vast majority of Medicare Part D beneficiaries still Don’t Choose The Cheapest Plans That Meet Their Medication Needs (Zhou & Zhang, p. 2259)
  • In Medicare Part D Plans, Low Or Zero Copays And Other Features To Encourage The Use Of Generic Statins Work, Could Save Billions (Hoadley, Merrell, Hargrave, & Summer, p. 2266)

Pharmaceuticals and Patents

  • The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment (Grabowski, Lakdawalla, Goldman, Eber, Liu, Abdelgawad, Kuznik, Chernew, & Philipson, p. 2276)
  • Secondary patenting of branded pharmaceuticals: A case study of how patents on two HIV drugs could be extended for decades (Amin & Kesselheim, p. 2286)

Hospitals

  • Simulation shows hospitals that cooperate on infection control obtain better research than hospitals acting alone (Lee, Bartsch, Wong, Yilmaz, Dong, Kim, Brown, Potter, Platt, & Huang, p. 2295)

Medical Devices

  • Median approval times for class III medical devices have been well above statutory deadline set for FDA and CMS (Zinn, Allen, Jr., & Hacker, p. 2304)

Web First

  • Making greater use of dedicated hospital observation units for many short- stay patients could save $3.1 billion a year (Baugh, Venkatesh, Hilton, Samuel, Schuur, & Bohan, p. 2314)
  • Health benefits in 2012: Moderate premium increases for employer-sponsored plans; Young adults gained coverage under ACA (Glaxton, Rae, Panchal, Damico, Whitmore, Kenward, & Osei-Anto, p. 2324)
  • The new era of payment reform, spending targets, and cost containment in Massachusetts; Early lessons for the nation (Mechanic, Altman, McDonough, p. 2334)

Narrative Matters

  • Physician-assisted death is illegal in most states, so my patient made another choice (Muller, p. 2343)

Grantwatch

  • Update on funding to improve minority health and reduce health disparities (p. 2347)
 

Comments are closed.

(813) 974-2729  4202 E. Fowler Ave. LIB122 Tampa FL 33620  Home  News & Events  © Copyright 2014